Browsing NTNU Open by Author "Wader, Karin Fahl"
Now showing items 1-5 of 5
-
Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B
Olsen, Oddrun Elise; Wader, Karin Fahl; Hella, Hanne; Mylin, Anne K.; Turesson, Ingemar; Nesthus, Ingerid; Waage, Anders; Sundan, Anders; Holien, Toril (Journal article; Peer reviewed, 2015)Background: Activins are members of the TGF-β family of ligands that have multiple biological functions in embryonic stem cells as well as in differentiated tissue. Serum levels of activin A were found to be elevated ... -
Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin
Olsen, Oddrun Elise; Wader, Karin Fahl; Misund, Kristine; Våtsveen, Thea Kristin; Rø, Torstein Baade; Mylin, Anne K.; Turesson, I; Størdal, Berit Fladvad; Moen, Siv Helen; Standal, Therese; Waage, Anders; Sundan, Anders; Holien, Toril (Journal article; Peer reviewed, 2014)Multiple myeloma is a malignancy of plasma cells predominantly located in the bone marrow. A number of bone morphogenetic proteins (BMPs) induce apoptosis in myeloma cells in vitro, and with this study we add BMP-9 to the ... -
BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis
Rustad, Even Holth; Dai, Hong Yan; Hov, Håkon; Coward, Eivind; Beisvag, Vidar; Myklebost, Ola; Hovig, Eivind; Nakken, Sigve; Vodak, Daniel; Meza-Zepeda, Leonardo A.; Sandvik, Arne Kristian; Wader, Karin Fahl; Misund, Kristine; Sundan, Anders; Aarset, Harald; Waage, Anders (Journal article; Peer reviewed, 2015)In this study, we analyzed the prevalence and clone size of BRAF V600E mutation in 209 patients with multiple myeloma and related the results to clinical phenotype, response and survival. Biopsies were screened for BRAF ... -
Hepatocyte growth factor, c-Met and syndecan-1 in multiple myeloma
Wader, Karin Fahl (Doktoravhandlinger ved NTNU, 1503-8181; 2011:267, Doctoral thesis, 2011)HEPATOCYTT-VEKSTFAKTOR, C-MET OG SYNDECAN-1 I MYELOMATOSE Myelomgruppen ved IKM forsker på sykdommen myelomatose, en form for benmargskreft. Gruppens arbeid har vært fokusert på hvordan miljøet i benmargen, med løselige ... -
Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination
Riise, Jon; Meyer, Saskia; Blaas, Isaac; Chopra, Adity; Tran, Trung; Delic-Sarac, Marina; Hestdalen, Malu Lian; Brodin, Ellen Elisabeth; Rustad, Even Holth; Dai, Ke-Zheng; Vaage, John T.; Nissen-Meyer, Lise Sofie Haug; Sund, Fredrik; Wader, Karin Fahl; Bjørnevik, Anne Turid; Meyer, Peter Albert; Nygaard, Gro Owren; König, Marton; Smeland, Sigbjørn; Lund-Johansen, Fridtjof; Olweus, Johanna; Kolstad, Arne (Peer reviewed; Journal article, 2022)B-cell depletion induced by anti-cluster of differentiation 20 (CD20) monoclonal antibody (mAb) therapy of patients with lymphoma is expected to impair humoral responses to severe acute respiratory syndrome coronavirus-2 ...